PCSK9 inhibitor

PCSK9 inhibitors are a class of drugs used primarily in the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. They work by blocking the action of the protein PCSK9 (proprotein convertase subtilisin/kexin type 9), thereby increasing the number of low-density lipoprotein (LDL) receptors on the surface of liver cells, which results in a decrease in circulating LDL cholesterol levels.

Mechanism of Action

PCSK9 inhibitors work by binding to PCSK9, a protein that targets LDL receptors for degradation. By inhibiting PCSK9, these drugs increase the number of LDL receptors available to clear LDL, often referred to as "bad cholesterol", from the bloodstream. This results in a decrease in the level of LDL cholesterol, which is a major risk factor for cardiovascular disease.

Clinical Use

PCSK9 inhibitors are used in the treatment of hypercholesterolemia and mixed dyslipidemia. They are typically used in patients who have not responded adequately to other cholesterol-lowering treatments, such as statins or ezetimibe, or in patients who are unable to tolerate these treatments due to side effects. PCSK9 inhibitors have been shown to significantly reduce LDL cholesterol levels and are also associated with a reduction in cardiovascular events.

Examples of PCSK9 inhibitors

There are currently three PCSK9 inhibitors approved for use by the Food and Drug Administration (FDA): alirocumab (Praluent), evolocumab (Repatha), and bococizumab (not marketed). These drugs are administered by subcutaneous injection.

Side Effects

Common side effects of PCSK9 inhibitors include injection site reactions, nasopharyngitis, and flu-like symptoms. Serious side effects are rare but can include allergic reactions.

Future Directions

Research is ongoing to develop oral PCSK9 inhibitors, which would provide a more convenient administration route compared to subcutaneous injection. In addition, studies are being conducted to further understand the long-term effects of PCSK9 inhibition on cardiovascular outcomes.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian